$IQV

Patel Bhavik sold $436K of IQV

Patel Bhavik (See Remarks) sold 1,855 shares of IQVIA HOLDINGS INC. (IQV) at $235.27 ($0.44M total) on 2026-07-31.

Original reporting
SEC EDGAR · Patel Bhavik
Published Aug 4, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new operational, financial, or regulatory information about IQVIA.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no direct fundamental catalyst in the text.

03

What to watch

Insider sales are often driven by taxes, diversification, or pre-existing compensation schedules; without stated purpose, the signal quality is low.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04 after-hours; sale dated 2026-07-31

Background

The article is a SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer Patel Bhavik sold 1,855 shares on 2026-07-31 at $235.27 for about $436.4K.

Expected impact

Likely limited near-term impact; any effect would be brief and sentiment-driven rather than a fundamental repricing.

Evidence & confidence

The filing discloses transaction size and price but provides no new company performance, guidance, or regulatory/legal catalyst. Insider sales can be non-informational, and the article lacks additional context (e.g., compensation, tax, diversification).

Market effects

Minimal; insider-sale disclosures rarely change sector fundamentals for healthcare services/pharma services.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as potentially more informative than typical planned sales, even though the article provides no rationale.

Key entities

  • IQVIA HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Patel Bhavik

    Officer who sold 1,855 shares in an open-market sale.

Related articles

$IQVMed

5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call

IQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.

Med

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

IQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.

MedAI 8/10

IQVIA Holdings Inc. Q2 2026 Earnings Call Summary

IQVIA reported Q2 2026 results and said organic revenue growth accelerated to 6% YoY, driven by improving market conditions and execution. Management raised full-year 2026 guidance, citing 100 bps higher organic growth and more M&A contribution. It expects flat adjusted EBITDA margins around 23.2% and noted Charles River asset acquisition added 50 bps to M&A growth.

$IQVMedAI 8/10

IQVIA Holdings (IQV) Soars on Revenue Growth Outlook, Strong Q2

IQVIA Holdings (NYSE:IQV) rose after reporting strong Q2 results and raising its full-year revenue growth outlook. Q2 revenue grew 8.7% to $4.37B, while attributable net income fell 3.7% to $256M. FY26 revenue guidance increased to $17.275B-$17.475B, with adjusted EBITDA $4.0B-$4.05B and buybacks of $2.819B authorized.